EGFR Mutation Testing Practices within the Asia Pacific Region: Results of a Multicenter Diagnostic Survey

Abstract

Introduction:The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR mutation-positive non–small-cell lung cancer (NSCLC) patients necessitates accurate, timely testing. Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods.Methods:A retrospective survey of records from NSCLC patients tested for EGFR mutations during 2011 was conducted in 11 Asian Pacific countries at 40 sites that routinely performed EGFR mutation testing during that period. Patient records were used to complete an online questionnaire at each site.Results:Of the 22,193 NSCLC patient records surveyed, 31.8% (95% confidence interval: 31.2%–32.5%) were tested for EGFR mutations. The rate of EGFR mutation positivity was 39.6% among the 10,687 cases tested. The majority of samples were biopsy and/or cytology samples (71.4%). DNA sequencing was the most commonly used testing method accounting for 40% and 32.5% of tissue and cytology samples, respectively. A pathology report was available only to 60.0% of the sites, and 47.5% were not members of a Quality Assurance Scheme.Conclusions:In 2011, EGFR mutation testing practices varied widely across Asia. These data provide a reference platform from which to improve the molecular diagnosis of NSCLC, and EGFR mutation testing in particular, in Asia.

A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506)

“…The sample size calculation assumed an EGFR gene mutation rate of 30% for East Asian populations [11], data from 897 patients to provide 2-sided 95% confidence intervals (CIs) with a precision of 3%, and exclusion of 5 to 10% of MERAFs because of missing data or other errors. Thus, collection of data from 1000 patients was planned.…”

Characteristics of clinical N0 metastatic non-small cell lung cancer

“…Considering the results of multivariate analysis of favorable prognostic factors, patients with metastasis to a single site except for liver and adrenal gland would benefit from an aggressive therapy. Furthermore, although molecular targeted drugs contributed to the paradigm shift of therapeutic strategies, approximately half of the NSCLC patients who have neither EGFR mutation nor ALK rearrangement still do not benefit from molecular targeted agents [32][33][34]. Thus, we do feel that the data in this study are beneficial even in this era of molecular-targeted therapy.…”

A highly specific and sensitive massive parallel sequencer-based test for somatic mutations in non-small cell lung cancer

“…Accordingly, tests for epidermal growth factor receptor ( EGFR ) mutations [4, 5] and the fusion gene of the anaplastic lymphoma receptor kinase ( ALK ) [6, 7] have been introduced in clinical practice in many countries [8–10]. Drugs targeting several other cancer driver genes [11] have entered the market, and many others will follow in the near future.…”